MedTrace Logo

Efficacy Of Itraconazole In Chronic Cavitary Pulmonary Aspergillosis

NCT01259336 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2012-02-22

No results posted yet for this study

Summary

The purpose of this study is to determine whether there itraconazole is effective in the treatment of chronic cavitary pulmonary aspergillosis

Conditions

  • Chronic Cavitary Pulmonary Aspergillosis

Interventions

DRUG

Itraconazole

Tablet 200 mg twice daily for 6 months

DRUG

treatment in cavitary pulmonary aspergillosis

Anti-tussive, blood transfusion, surgical resection and bronchial artery embolisation(BAE)

Sponsors & Collaborators

  • Post Graduate Institute of Medical Education and Research, Chandigarh

    lead OTHER

Principal Investigators

  • Vishwananath gella, DM · Post Graduate Institute of Medical Education and Research, Chandigarh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2011-06-30
Completion
2011-12-31

Countries

  • India

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01259336 on ClinicalTrials.gov